At Rgenta, we are redefining what’s possible in drug discovery by targeting RNA and RNA regulation. By harnessing the power of genomic data, we can pinpoint precise, high-impact RNA target sites. We select orally available small molecules from our specialized compound libraries tailored to engage these RNA target sites and key RNA-binding regulatory proteins to modulate their function with high specificity. Thus, we can prevent the production of disease-associated proteins and develop therapies where traditional approaches have failed.